EyePoint Business Update
EyePoint is implementing a strategic prioritization plan that includes a 53% workforce reduction and the early conclusion of its Phase 3 wet AMD clinical trials after the LUCIA study failed to meet its primary endpoint. The company will focus its remaining resources on the development of DURAVYU for diabetic macular edema (DME), expecting to save approximately $30 million annually while incurring $9 million in one-time restructuring charges.